CRCU

Chemical Research in Chinese Universities ›› 2006, Vol. 22 ›› Issue (2): 213-216.

• Articles • Previous Articles     Next Articles

Construction of Recombinant Modified Vaccinia Ankara (MVA) Expressing Hepatitis B Virus Surface Antigen

CHEN Yu, YANG Xiao-song, YU Xiang-hui, JIANG Chun-lai, WU Yong-ge, JIN Ying-hua, CHEN Yue, CHEN Yan, LI Wei, KONG Wei   

  1. Vaccine Research Center, College of Life Science, Jilin University, Changchun 130012, P.R.China
  • Received:2005-12-31 Online:2006-04-24 Published:2011-08-06

PDF (PC)

Abstract: The T lymphocyte response has been shown to be the determinant in the clearance of many viral infections.Hence, therapeutic vaccine candidates against HBV are designed to enhance this response of the immune system.Vaccinia virus vector-based vaccines have been proposed as excellent candidates to elicit long-term and strong T lymphocyte mediated immune responses.In this study, the recombinant MVA expressing HBV surface antigen has been constructed, which can elicit a potent T cell mediated response.The ELISA results for the surface protein in the medium of the recombinant MVA, strongly indicate that the recombinant virus has been successfully obtained.

Key words: Recombinant MVA, Therapeutic vaccine, T lymphocyte response